Skip to main navigation
Alaunos Logo
  • TCR-T CELL THERAPY
    • OUR APPROACH
    • OUR SCIENCE
    • MANUFACTURING
  • PIPELINE
    • CLINICAL TRIALS
  • PATIENTS
  • PARTNERING
    • CONTROLLED IL-12
    • CAR-T THERAPIES
  • ABOUT
    • MANAGEMENT TEAM
    • BOARD OF DIRECTORS
    • SCIENTIFIC ADVISORY BOARD
    • PARTNERSHIPS
    • SCIENTIFIC PUBLICATIONS
    • CAREERS
    • HOUSTON
    • CONTACT
  • INVESTORS
    • INVESTORS HOME
    • PRESS RELEASES
    • Stock Performance
      • STOCK INFORMATION
      • HISTORIC STOCK LOOKUP
    • SEC FILINGS
    • EVENTS & PRESENTATIONS
    • QUARTERLY RESULTS
    • Corporate Governance
      • BOARD OF DIRECTORS
      • COMMITTEES & CHARTERS
    • ANALYST COVERAGE
    • INVESTOR FAQS
Menu
  • TCR-T CELL THERAPY
    • OUR APPROACH
    • OUR SCIENCE
    • MANUFACTURING
  • PIPELINE
    • CLINICAL TRIALS
  • PATIENTS
  • PARTNERING
    • CONTROLLED IL-12
    • CAR-T THERAPIES
  • ABOUT
    • MANAGEMENT TEAM
    • BOARD OF DIRECTORS
    • SCIENTIFIC ADVISORY BOARD
    • PARTNERSHIPS
    • SCIENTIFIC PUBLICATIONS
    • CAREERS
    • HOUSTON
    • CONTACT
  • INVESTORS
    • INVESTORS HOME
    • PRESS RELEASES
    • Stock Performance
      • STOCK INFORMATION
      • HISTORIC STOCK LOOKUP
    • SEC FILINGS
    • EVENTS & PRESENTATIONS
    • QUARTERLY RESULTS
    • Corporate Governance
      • BOARD OF DIRECTORS
      • COMMITTEES & CHARTERS
    • ANALYST COVERAGE
    • INVESTOR FAQS

Quarterly
Results

Show all

2022

Q3
  • Alaunos Therapeutics Third Quarter 2022 Financial Results Conference Call
  • Earnings Presentation 4 MB
  • Alaunos Therapeutics Reports Third Quarter 2022 Financial Results
  • Form 10-Q
Q2
  • Alaunos Therapeutics Reports Second Quarter 2022 Financial Results
  • form 10-Q
Q1
  • Alaunos Therapeutics Reports First Quarter 2022 Financial Results
  • Form 10-Q
Email Alerts Subscription
RSS News Feeds
Print

  • Facebook
  • LinkedIn
  • Twitter
  • RSS
Alaun logo

Privacy Policy  •   Terms of Use

© 2023 Alaunos Therapeutics, Inc.
Linkedin